311 related articles for article (PubMed ID: 21927021)
1. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
Ali AY; Abedini MR; Tsang BK
Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
[TBL] [Abstract][Full Text] [Related]
2. Akt confers cisplatin chemoresistance in human gynecological carcinoma cells by modulating PPM1D stability.
Ali AY; Kim JY; Pelletier JF; Vanderhyden BC; Bachvarov DR; Tsang BK
Mol Carcinog; 2015 Nov; 54(11):1301-14. PubMed ID: 25154814
[TBL] [Abstract][Full Text] [Related]
3. PPM1D dephosphorylates Chk1 and p53 and abrogates cell cycle checkpoints.
Lu X; Nannenga B; Donehower LA
Genes Dev; 2005 May; 19(10):1162-74. PubMed ID: 15870257
[TBL] [Abstract][Full Text] [Related]
4. Sensitization of cis-platinum by a recombinant adenovirus vector expressing wild-type p53 gene in human ovarian carcinomas.
Song K; Li Z; Seth P; Cowan KH; Sinha BK
Oncol Res; 1997; 9(11-12):603-9. PubMed ID: 9563008
[TBL] [Abstract][Full Text] [Related]
5. Augmented cancer resistance and DNA damage response phenotypes in PPM1D null mice.
Nannenga B; Lu X; Dumble M; Van Maanen M; Nguyen TA; Sutton R; Kumar TR; Donehower LA
Mol Carcinog; 2006 Aug; 45(8):594-604. PubMed ID: 16652371
[TBL] [Abstract][Full Text] [Related]
6. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells.
Fraser M; Leung BM; Yan X; Dan HC; Cheng JQ; Tsang BK
Cancer Res; 2003 Nov; 63(21):7081-8. PubMed ID: 14612499
[TBL] [Abstract][Full Text] [Related]
7. P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
Al-Bahlani S; Fraser M; Wong AY; Sayan BS; Bergeron R; Melino G; Tsang BK
Oncogene; 2011 Oct; 30(41):4219-30. PubMed ID: 21516125
[TBL] [Abstract][Full Text] [Related]
8. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein (PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking.
Woo MG; Xue K; Liu J; McBride H; Tsang BK
J Biol Chem; 2012 Feb; 287(6):3963-75. PubMed ID: 22117079
[TBL] [Abstract][Full Text] [Related]
9. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
[TBL] [Abstract][Full Text] [Related]
10. Drug-dependent functionalization of wild-type and mutant p53 in cisplatin-resistant human ovarian tumor cells.
Bhatt M; Ivan C; Xie X; Siddik ZH
Oncotarget; 2017 Feb; 8(7):10905-10918. PubMed ID: 28038466
[TBL] [Abstract][Full Text] [Related]
11. p53 is required for cisplatin-induced processing of the mitochondrial fusion protein L-Opa1 that is mediated by the mitochondrial metallopeptidase Oma1 in gynecologic cancers.
Kong B; Wang Q; Fung E; Xue K; Tsang BK
J Biol Chem; 2014 Sep; 289(39):27134-27145. PubMed ID: 25112877
[TBL] [Abstract][Full Text] [Related]
12. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
13. Reversal of the ATM/ATR-mediated DNA damage response by the oncogenic phosphatase PPM1D.
Lu X; Nguyen TA; Donehower LA
Cell Cycle; 2005 Aug; 4(8):1060-4. PubMed ID: 15970689
[TBL] [Abstract][Full Text] [Related]
14. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein.
Abedini MR; Muller EJ; Bergeron R; Gray DA; Tsang BK
Oncogene; 2010 Jan; 29(1):11-25. PubMed ID: 19802016
[TBL] [Abstract][Full Text] [Related]
15. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
16. The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
Im-aram A; Farrand L; Bae SM; Song G; Song YS; Han JY; Tsang BK
PLoS One; 2013; 8(9):e75455. PubMed ID: 24086535
[TBL] [Abstract][Full Text] [Related]
17. SB225002 promotes mitotic catastrophe in chemo-sensitive and -resistant ovarian cancer cells independent of p53 status in vitro.
Du M; Qiu Q; Gruslin A; Gordon J; He M; Chan CC; Li D; Tsang BK
PLoS One; 2013; 8(1):e54572. PubMed ID: 23359652
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
19. Resveratrol causes Cdc2-tyr15 phosphorylation via ATM/ATR-Chk1/2-Cdc25C pathway as a central mechanism for S phase arrest in human ovarian carcinoma Ovcar-3 cells.
Tyagi A; Singh RP; Agarwal C; Siriwardana S; Sclafani RA; Agarwal R
Carcinogenesis; 2005 Nov; 26(11):1978-87. PubMed ID: 15975956
[TBL] [Abstract][Full Text] [Related]
20. Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity.
Bulavin DV; Demidov ON; Saito S; Kauraniemi P; Phillips C; Amundson SA; Ambrosino C; Sauter G; Nebreda AR; Anderson CW; Kallioniemi A; Fornace AJ; Appella E
Nat Genet; 2002 Jun; 31(2):210-5. PubMed ID: 12021785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]